Effects of clomiphene citrate on endometrial hyperplasia in the premenopausal female

Robert W. Kistner, John L. Lewis, Gillen J. Steiner
In: Cancer · 1966 · vol. 19(1) , pp. 115–126 · doi:10.1002/1097-0142(196601)19:1<115::aid-cncr2820190113>3.0.co;2-f · PMID:5948088 · W1990373572
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-20 ⓘ

Clomiphene citrate temporarily treated endometrial hyperplasia in six premenopausal and postmenopausal women by inducing atypical secretory endometrium or normal menstrual cycles, though therapeutic effects ceased after treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Clomiphene was administered continuously in a dose of 100 to 200 mg daily for 16 to 18 months to 6 patients (5 approaching menopause and one postmenopausal) having endometrial hyperplasia with a presenting complaint of irregular and profuse bleeding. After cessation of clomiphene therapy the results were atypical secretory endometrium—2 patients; normal menstrual cycles—3 patients; spontaneous menopause—one patient. The therapeutic effects of clomiphene are temporary. If the ovary maintains its potential for follicular maturation and ovulation, a secretory phase will be induced in the endometrium which lasts 6 to 8 weeks. Endometrial atrophy then will develop and remain unchanged as long as therapy is continued. The major side effects of clomiphene are hot flashes and ovarian cysts.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (19)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK